What is Genoptix?
Genoptix operates as a premier clinical oncology laboratory, maintaining one of the most extensive hematopathology centers in the country. The organization specializes in the intricate analysis of hematology and solid tumors, leveraging advanced molecular testing to support hematologists, oncologists, and pathologists. By integrating comprehensive case management with actionable diagnostic insights, Genoptix facilitates personalized treatment pathways for patients suffering from bone marrow, blood, and lymph node disorders. Its diagnostic infrastructure is designed to bridge the gap between complex laboratory data and clinical decision-making, ensuring that referring physicians receive timely and accurate information for patient care.
How much funding has Genoptix raised?
Genoptix has raised a total of $28M across 1 funding round:
Other Financing Round
$28M
Other Financing Round (2018): $28M, investors not publicly disclosed
Key Investors in Genoptix
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Genoptix?
With this recent capital injection, Genoptix is well-positioned to scale its molecular testing operations and enhance its integrated diagnostic platform. The strategic focus will likely shift toward expanding its footprint in solid tumor workups and investing in proprietary diagnostic technologies that improve turnaround times and diagnostic sensitivity. As the oncology sector moves toward increasingly personalized medicine, Genoptix is poised to leverage its existing laboratory infrastructure to capture additional market share, potentially through the adoption of next-generation sequencing and expanded clinical partnerships. The firm remains a pivotal player in the diagnostic ecosystem, with a clear trajectory toward long-term operational growth and clinical excellence.
See full Genoptix company page
